🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

11 recruiting trials

for Resectable Stage II-IIIa NSCLC

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342Phase 23 sites📍 Beijing📍 Guangzhou📍 Zhejiang Jianxing He · Tests: fulzerasib Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC NCT03694236Phase 1, Phase 21 site📍 Seoul Yonsei University · Tests: durvalumab Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC NCT06810609Phase 25 sites📍 Freiburg im Breisgau📍 Stuttgart📍 Giessen University Hospital, Bonn · Tests: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance… Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients NCT06987734Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC NCT07398937Phase 21 site📍 Shanghai Fudan University · Tests: Serplulimab + chemotherapy, Nivolumab + chemotherapy Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC NCT07554846Phase 31 site📍 Shanghai Fudan University · Tests: Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC NCT06241807Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Camrelizumab Plus Chemotherapy Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery NCT06109454n/a1 site📍 Shenyang Liaoning Cancer Hospital & Institute · Tests: Huaier granule, Control D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC NCT07016126Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: D-BACE in combination with chemotherapy and karelizumab Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC NCT04865250Phase 21 site📍 Heidelberg University Hospital Heidelberg · Tests: Atezolizumab 1200 mg abs day 1 q22 (iv) Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer NCT06918132Phase 22 sites📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Cemiplimab, Fianlimab, Magnetic Resonance Imaging, Surgical Procedure
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy